Back to top


MS Australia's advocacy team is regularly looking for opportunities to contribute to policy development and government reviews.


MS Australia Submissions:

Note: (1) : joint submission with MS
(2) : joint submission with MS Research Australia
                (3) : joint submission with Neurological Alliance Australia (NAA)

                (4) : joint submission with Assistive Technology for All Alliance (ATFA)


Letter to Minister Stuart Robert regarding NDIS Independent assessment
Report on the Impact of the intro of Independent Assessment on People with MS
NDIS Review of Support Coordination
Joint Standing Committee on the NDIS inquiry into the NDIS Quality and Safeguards Commission
NDIS Consultation on Supported Independent Living
Inquiry into approval processes for new drugs and novel medical technologies in Australia (2)
Disability Royal Commission (Rights & Attitudes Issues Paper) (4)
Therapeutic Goods Administration Consultation: Proposed amendments to the Poisons Standard regarding cannabidiol (2)
Victorian State Disability Plan 2021-2024 Consultation (4)
NDIS Workforce



Pre-budget Submission (4)
Senate inquiry into barriers to access to medicinal cannabis (2)
ATFA submission to the Royal Commission into Aged Care Quality and Safety, December 2019 (4)
NAA submission to the Royal Commission into Aged Care Quality and Safety, August 2019 (3)
NDIS Planning
NDIS Supported Independent Living
NDIS Thin Markets Project
Royal Commission into Aged Care Quality & Safety
Streamlined Consumer Assessment for Aged Care



My Health Record 
Assistive Technology in the NDIS (1)
Qld Parliament Medicinal Cannabis Act (2)
Senate Select Committee Inquiry on Charity Fundraising
Implementation of the NDIS in NSW (1)
Vic Government Draft Disability Action Plan 2018-2020 (1)
Regulation of mobility scooters
Implementation of the NDIS in the ACT  (1)





Continuity of Support program
Pharmacy Remuneration and Regulation
New Disability Employment Services from 2018
ILC Commissioning framework
Election Commitments: Submission to the major parties for the 2016 Federal Election (2)
Vic State Disability Plan 2017-2020 (1)
Submission to the NDIS inquiry into accommodation for people with disabilities and the NDIS
Submission to TGA re Poisons Standard for Medicinal Cannabis (2)
Inquiry into the Public Health (Medicinal Cannabis) Bill - Qld (2)
Services for people with psychosocial disabilities



MS Australia Willing to Work Submission
NDIS Quality and Safeguard Framework Submission
Victorian Law Reform Commission's Medicinal Cannabis Issues Paper (2)
NDIS Information, Linkages and Capacity Building (ILC) Policy Framework
Senate Legal and Constitutional Affairs Legislation Committee Inquiry- Medicinal Cannabis Bill (2)
Young people in res care inquiry
Cannabis Use for Medical Purposes ACT bill (2)
TGA Regulations Stem Cells Submission
Disability Advocacy Framework consultation
Increasing choice in home care Stage 1
New aged care short-term restorative care program



McClure Welfare Review Submission
Airline two wheelchair policy
Federal Senate Inquiry - Out-of-pocket health costs



Legal capacity for people with a disability - National Disability Services review of legislation



MS Australia Submissions to the Pharmaceutical Benefits Advisory Committee:

One area of advocacy we are particularly passionate about is advocating for greater access to affordable treatments for people with MS. MSA and MS Research Australia work together closely on treatment and research advocacy. No two cases of MS are the same and there is no one size fits all treatment for the disease. MS Australia regularly makes submissions supporting the listing of MS treatments on the Pharmaceutical Benefits Scheme (PBS) so that people with MS and their neurologists have greater choice and flexibility to find the treatment method that best suits them. The research and medication information contained in these submissions is provided by MS Research Australia.

Eculizumab (Soliris ®) for NMOSD – joint submission with MS Research Australia and the Centre for Community-Driven Research
Ocrelizumab (Ocrevus®) for Primary Preogressive MS – July 2020 PBAC Review
Nabiximols (Sativex®) for spasticity in MS - March 2020 PBAC Review
Ozanimod (Zeposia®) for Relapsing Remitting MS (RRMS) - March 2020 PBAC Review
Siponimod (Mayzent®) for Secondary Progressive MS (SPMS) - March 2020 PBAC Review

Fingolimod (Gilenya) for under 40kg - July 2019 PBAC Review
Natalizumab (Tysabri) for all ages - July 2019 PBAC Review

Cladribine (MAVENCLAD) for RRMS re-submission – July PBAC Review
Cladribine (AVENCLAD) for RRMS re-submission – March PBAC Review

Glatiramer acetate (Copaxone) for Clinically Isolated Syndrome -  PBAC Review
Clabribine (MAVENCLAD) for RRMS -  PBAC Review
Ocrelizumab (Ocrevus) for RRMS -  PBAC Review
Ocrelizumab (Ocrevus) for PPMS -  PBAC Review

Daclizumab (Zinbryta) - PBAC Review

Glatiramer acetate (Copaxone) 40 - PBAC Review

Expressed Authority -  PBAC Review
Fampridine (Fampyra) - PBAC Review
Alemtuzumab (Lemtrada) - PBAC Review
Alemtuzumab (Lemtrada) (additional) - PBAC Review
Peginterferon beta-1a (Plegridy) - PBAC Review

Teriflunomide (Aubagio) - PBAC Review
Dimethyl Fumarate (Tecfidera) - PBAC Review